Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Thrombocytopenia 1Cytopenia 1Anemia 1

Interventions

AP 1903 reagent 3ON 01910 2Biopsy 2thymoglobulin 1fludarabine phosphate 1fludarabine 1epacadostat 1decitabine and cedazuridine drug combination 1cedazuridine 1angiotensin I (1-7) 1Vitamin B 12 1Therapeutics 1Specimen Handling 1Sertraline 1Pluvicto 1Peripheral Blood Stem Cell Transplantation 1Metformin 1Interleukin-8 1Immunotherapy, Adoptive 1IDO-1 inhibitor LY3381916 1HuMax-IL8 1Granulocyte Colony-Stimulating Factor 1Genetic Counseling 1Folic Acid 1Filgrastim 1Exercise 1Emapalumab 1Decitabine 1DNA 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytopenia × Pluvicto × Classical hematology × Clear all
NCT07025512 2026-05-08

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Classical hematology

Cytopenia, Anemia, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡